Cargando…
Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1‐year patient‐level meta‐analysis of the EDITION clinical studies in people with type 2 diabetes
AIMS: To investigate the efficacy and safety of insulin glargine 300 U/mL (Gla‐300) vs insulin glargine 100 U/mL (Gla‐100) over 12 months in a patient‐level meta‐analysis, using data from the EDITION studies in people with type 2 diabetes (T2DM). METHODS: EDITION 1, 2 and 3 were multicentre, randomi...
Autores principales: | Ritzel, Robert, Roussel, Ronan, Giaccari, Andrea, Vora, Jiten, Brulle‐Wohlhueter, Claire, Yki‐Järvinen, Hannele |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836995/ https://www.ncbi.nlm.nih.gov/pubmed/28862801 http://dx.doi.org/10.1111/dom.13105 |
Ejemplares similares
-
Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes
por: Ritzel, R, et al.
Publicado: (2015) -
Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial
por: Bolli, Geremia B., et al.
Publicado: (2021) -
Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4)
por: Home, Philip D., et al.
Publicado: (2017) -
Low Blood Glucose Index and Hypoglycaemia Risk: Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Type 2 Diabetes
por: Kovatchev, Boris, et al.
Publicado: (2020) -
Ease of Use of the Insulin Glargine 300 U/mL Pen Injector in Insulin-Naïve People With Type 2 Diabetes
por: Pohlmeier, Harald, et al.
Publicado: (2017)